We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 4 oktober 2018

The Lancet: [Articles] Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-wee...

[Articles] Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes.
Read more

[Comment] Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
A growing number of clinical trials have shown that home use of hybrid closed-loop insulin delivery systems reduces time spent in hypoglycaemia and improves time in target ranges for those with type 1 diabetes.1–6 In September, 2016, the first commercially available hybrid closed-loop insulin delivery system for management of type 1 diabetes was approved by the US Food and Drug Administration for patients aged 15 years and older. Approval of this system was supported by a non-randomised trial in which the primary outcome was safety.
Read more

[World Report] UN High-Level meeting to end tuberculosis disappointing
A high-level meeting in which a political declaration to end tuberculosis was agreed upon fell short of expectations, experts say. Sophie Cousins reports.
Read more

[Department of Error] Department of Error
Walker KF, Thornton JG. Encouraging awareness of fetal movements is harmful. Lancet 2018; published online September 27. http://dx.doi.org/10.1016/S0140-6736(18)31720-3—This Comment is eligible for Open Access. The copyright line has been added. This correction has been made to the online version as of Oct 3, 2018.
Read more

[Articles] Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
The dual GIP and GLP-1 receptor agonist, LY3298176, showed significantly better efficacy with regard to glucose control and weight loss than did dulaglutide, with an acceptable safety and tolerability profile. Combined GIP and GLP-1 receptor stimulation might offer a new therapeutic option in the treatment of type 2 diabetes.
Read more